China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China
SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited (“CMS” or…
1,435€
-2,38%
Echtzeit-Aktienkurs CHINA M.SYS.H.CONS.DL-005
Bid:
Ask:
Nachrichten zur CHINA M.SYS.H.CONS.DL-005 Aktie
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
SHENZHEN, CHINA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its…
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its…
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”,…
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…